Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia
Background Geographic differences exist in the antibiotic resistance patterns of Helicobacter pylori. Personalized treatment regimens based on local or individual resistance data are essential. We evaluated the current status of H. pylori resistance in Ningxia, analyzed resistance‐related factors, a...
Gespeichert in:
| Veröffentlicht in: | Helicobacter (Cambridge, Mass.) Mass.), 2023-06, Vol.28 (3), p.e12960-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e12960 |
| container_title | Helicobacter (Cambridge, Mass.) |
| container_volume | 28 |
| creator | Hu, Shengjuan Zhou, Yan Deng, Yanhong Bo, Yang Chen, Xianmei Yang, Wei Shi, Ruichun Zhao, Wei Hou, Zhanbing Hu, Jianping Liu, Jianguo Zhang, Xilong Yong, Heli Wang, Ping Li, Fei Qi, Hailong Wang, Xiaoyun Jin, Lijuan Cui, Ting Yong, Haijiang Li, Xue Yang, Bin Yu, Yuehua Ma, Bin Fu, Lei Wang, Xuemei Ma, Zhen Tang, Na You, Yanjie Guo, Jianyang Yu, Xiaobing Yao, Li Gao, Ruiping Li, Yanling Xin, Ruijuan Liu, Jianfang Cao, Zhenzi Li, Hongliang Ma, Linke Ma, Shoucheng Cao, Ying Tang, Yuanyuan Liu, Jun Hao, Qian Li, Xiaofei Li, Xuemei Mu, Rui Niu, Min Su, Xiaoming Gao, Hengjun |
| description | Background
Geographic differences exist in the antibiotic resistance patterns of Helicobacter pylori. Personalized treatment regimens based on local or individual resistance data are essential. We evaluated the current status of H. pylori resistance in Ningxia, analyzed resistance‐related factors, and assessed the concordance of phenotypic and genotypic resistance.
Methods
Strains were isolated from the gastric mucosa of patients infected with H. pylori in Ningxia and relevant clinical information was collected. Phenotypic antibiotic susceptibility assays (Kirby–Bauer disk diffusion) and antibiotic resistance gene detection (Sanger sequencing) were performed.
Results
We isolated 1955 H. pylori strains. The resistance rates of H. pylori to amoxicillin, levofloxacin, clarithromycin, and metronidazole were 0.9%, 42.4%, 40.4%, and 94.2%, respectively. Only five tetracycline‐resistant and one furazolidone‐resistant strain were identified. Overall, 3.3% of the strains were sensitive to all six antibiotics. Multidrug‐resistant strains accounted for 22.9%, of which less than 20% were from Wuzhong. Strains isolated from women and patients with nonulcerative disease had higher rates of resistance to levofloxacin and clarithromycin. Higher rates of resistance to metronidazole, levofloxacin, and clarithromycin were observed in the older age group than in the younger age group. The kappa coefficients of phenotypic resistance and genotypic resistance for levofloxacin and clarithromycin were 0.830 and 0.809, respectively, whereas the remaining antibiotics showed poor agreement.
Conclusion
H. pylori antibiotic resistance is severe in Ningxia. Therefore, furazolidone, amoxicillin, and tetracycline are better choices for the empirical therapy of H. pylori infection in this region. Host sex, age, and the presence of ulcerative diseases may affect antibiotic resistance of the bacteria. Personalized therapy based on genetic testing for levofloxacin and clarithromycin resistance may be a future direction for the eradication therapy of H. pylori infection in Ningxia. |
| doi_str_mv | 10.1111/hel.12960 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2800149026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2800149026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-6418318115ac2c3884087601f4ab6288bf3221701f3c33c281dbdaa84aa8c4093</originalsourceid><addsrcrecordid>eNp9kctKxDAUhoMo3he-gATc6KKaW9vUnQzqCINudF3SNHWOdJqapGofyPc046gLQQMhycl3PhJ-hA4oOaVxnM1Ne0pZkZE1tE1TxpOU53I97onkieCy2EI73j8RQlIuik20xXMiGBHpNnqfzJVTOhgHPoD22Da4n5vOhrEHjVUXoAIbb7AzPiKq02bJTE0L2lafnbgfW-sgwjWG4LG2zplWBbAdfoUwx4__-87xRTwFZ31vdIAXg30Y6hFDh2-he3wDtYc2GtV6s_-17qKHq8v7yTSZ3V3fTC5mieZSkiQTVHIqKU2VZsuSIDLPCG2EqjImZdVwxmgeC1xzrpmkdVUrJUWcWpCC76Ljlbd39nkwPpQL8Nq0reqMHXzJJCFUFIRlET36hT7ZwXXxdUuq4DTPszxSJytKx995Z5qyd7BQbiwpKZfZlTG78jO7yB5-GYdqYeof8jusCJytgFdozfi3qZxezlbKD0bYpdI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2809317767</pqid></control><display><type>article</type><title>Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hu, Shengjuan ; Zhou, Yan ; Deng, Yanhong ; Bo, Yang ; Chen, Xianmei ; Yang, Wei ; Shi, Ruichun ; Zhao, Wei ; Hou, Zhanbing ; Hu, Jianping ; Liu, Jianguo ; Zhang, Xilong ; Yong, Heli ; Wang, Ping ; Li, Fei ; Qi, Hailong ; Wang, Xiaoyun ; Jin, Lijuan ; Cui, Ting ; Yong, Haijiang ; Li, Xue ; Yang, Bin ; Yu, Yuehua ; Ma, Bin ; Fu, Lei ; Wang, Xuemei ; Ma, Zhen ; Tang, Na ; You, Yanjie ; Guo, Jianyang ; Yu, Xiaobing ; Yao, Li ; Gao, Ruiping ; Li, Yanling ; Xin, Ruijuan ; Liu, Jianfang ; Cao, Zhenzi ; Li, Hongliang ; Ma, Linke ; Ma, Shoucheng ; Cao, Ying ; Tang, Yuanyuan ; Liu, Jun ; Hao, Qian ; Li, Xiaofei ; Li, Xuemei ; Mu, Rui ; Niu, Min ; Su, Xiaoming ; Gao, Hengjun</creator><creatorcontrib>Hu, Shengjuan ; Zhou, Yan ; Deng, Yanhong ; Bo, Yang ; Chen, Xianmei ; Yang, Wei ; Shi, Ruichun ; Zhao, Wei ; Hou, Zhanbing ; Hu, Jianping ; Liu, Jianguo ; Zhang, Xilong ; Yong, Heli ; Wang, Ping ; Li, Fei ; Qi, Hailong ; Wang, Xiaoyun ; Jin, Lijuan ; Cui, Ting ; Yong, Haijiang ; Li, Xue ; Yang, Bin ; Yu, Yuehua ; Ma, Bin ; Fu, Lei ; Wang, Xuemei ; Ma, Zhen ; Tang, Na ; You, Yanjie ; Guo, Jianyang ; Yu, Xiaobing ; Yao, Li ; Gao, Ruiping ; Li, Yanling ; Xin, Ruijuan ; Liu, Jianfang ; Cao, Zhenzi ; Li, Hongliang ; Ma, Linke ; Ma, Shoucheng ; Cao, Ying ; Tang, Yuanyuan ; Liu, Jun ; Hao, Qian ; Li, Xiaofei ; Li, Xuemei ; Mu, Rui ; Niu, Min ; Su, Xiaoming ; Gao, Hengjun</creatorcontrib><description>Background
Geographic differences exist in the antibiotic resistance patterns of Helicobacter pylori. Personalized treatment regimens based on local or individual resistance data are essential. We evaluated the current status of H. pylori resistance in Ningxia, analyzed resistance‐related factors, and assessed the concordance of phenotypic and genotypic resistance.
Methods
Strains were isolated from the gastric mucosa of patients infected with H. pylori in Ningxia and relevant clinical information was collected. Phenotypic antibiotic susceptibility assays (Kirby–Bauer disk diffusion) and antibiotic resistance gene detection (Sanger sequencing) were performed.
Results
We isolated 1955 H. pylori strains. The resistance rates of H. pylori to amoxicillin, levofloxacin, clarithromycin, and metronidazole were 0.9%, 42.4%, 40.4%, and 94.2%, respectively. Only five tetracycline‐resistant and one furazolidone‐resistant strain were identified. Overall, 3.3% of the strains were sensitive to all six antibiotics. Multidrug‐resistant strains accounted for 22.9%, of which less than 20% were from Wuzhong. Strains isolated from women and patients with nonulcerative disease had higher rates of resistance to levofloxacin and clarithromycin. Higher rates of resistance to metronidazole, levofloxacin, and clarithromycin were observed in the older age group than in the younger age group. The kappa coefficients of phenotypic resistance and genotypic resistance for levofloxacin and clarithromycin were 0.830 and 0.809, respectively, whereas the remaining antibiotics showed poor agreement.
Conclusion
H. pylori antibiotic resistance is severe in Ningxia. Therefore, furazolidone, amoxicillin, and tetracycline are better choices for the empirical therapy of H. pylori infection in this region. Host sex, age, and the presence of ulcerative diseases may affect antibiotic resistance of the bacteria. Personalized therapy based on genetic testing for levofloxacin and clarithromycin resistance may be a future direction for the eradication therapy of H. pylori infection in Ningxia.</description><identifier>ISSN: 1083-4389</identifier><identifier>EISSN: 1523-5378</identifier><identifier>DOI: 10.1111/hel.12960</identifier><identifier>PMID: 37042045</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Age ; Age groups ; Aged ; Amoxicillin ; Amoxicillin - therapeutic use ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotic resistance ; Antibiotics ; Clarithromycin ; Clarithromycin - pharmacology ; Clarithromycin - therapeutic use ; Customization ; Drug resistance ; Drug Resistance, Bacterial ; Drug Resistance, Microbial ; Empirical analysis ; eradication therapy ; Female ; Furazolidone ; Furazolidone - therapeutic use ; gastric disease ; Gastric mucosa ; Gene sequencing ; Genetic screening ; genotype ; Helicobacter Infections - drug therapy ; Helicobacter Infections - microbiology ; Helicobacter pylori ; Humans ; Levofloxacin ; Levofloxacin - pharmacology ; Levofloxacin - therapeutic use ; Metronidazole ; Metronidazole - pharmacology ; Metronidazole - therapeutic use ; Microbial Sensitivity Tests ; Patients ; phenotype ; Resistance factors ; Retrospective Studies ; Strains (organisms) ; Tetracycline - pharmacology ; Tetracycline - therapeutic use ; Therapy</subject><ispartof>Helicobacter (Cambridge, Mass.), 2023-06, Vol.28 (3), p.e12960-n/a</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023 The Authors. Helicobacter published by John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-6418318115ac2c3884087601f4ab6288bf3221701f3c33c281dbdaa84aa8c4093</citedby><cites>FETCH-LOGICAL-c3880-6418318115ac2c3884087601f4ab6288bf3221701f3c33c281dbdaa84aa8c4093</cites><orcidid>0000-0002-6676-8800</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhel.12960$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhel.12960$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37042045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Shengjuan</creatorcontrib><creatorcontrib>Zhou, Yan</creatorcontrib><creatorcontrib>Deng, Yanhong</creatorcontrib><creatorcontrib>Bo, Yang</creatorcontrib><creatorcontrib>Chen, Xianmei</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Shi, Ruichun</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Hou, Zhanbing</creatorcontrib><creatorcontrib>Hu, Jianping</creatorcontrib><creatorcontrib>Liu, Jianguo</creatorcontrib><creatorcontrib>Zhang, Xilong</creatorcontrib><creatorcontrib>Yong, Heli</creatorcontrib><creatorcontrib>Wang, Ping</creatorcontrib><creatorcontrib>Li, Fei</creatorcontrib><creatorcontrib>Qi, Hailong</creatorcontrib><creatorcontrib>Wang, Xiaoyun</creatorcontrib><creatorcontrib>Jin, Lijuan</creatorcontrib><creatorcontrib>Cui, Ting</creatorcontrib><creatorcontrib>Yong, Haijiang</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Yang, Bin</creatorcontrib><creatorcontrib>Yu, Yuehua</creatorcontrib><creatorcontrib>Ma, Bin</creatorcontrib><creatorcontrib>Fu, Lei</creatorcontrib><creatorcontrib>Wang, Xuemei</creatorcontrib><creatorcontrib>Ma, Zhen</creatorcontrib><creatorcontrib>Tang, Na</creatorcontrib><creatorcontrib>You, Yanjie</creatorcontrib><creatorcontrib>Guo, Jianyang</creatorcontrib><creatorcontrib>Yu, Xiaobing</creatorcontrib><creatorcontrib>Yao, Li</creatorcontrib><creatorcontrib>Gao, Ruiping</creatorcontrib><creatorcontrib>Li, Yanling</creatorcontrib><creatorcontrib>Xin, Ruijuan</creatorcontrib><creatorcontrib>Liu, Jianfang</creatorcontrib><creatorcontrib>Cao, Zhenzi</creatorcontrib><creatorcontrib>Li, Hongliang</creatorcontrib><creatorcontrib>Ma, Linke</creatorcontrib><creatorcontrib>Ma, Shoucheng</creatorcontrib><creatorcontrib>Cao, Ying</creatorcontrib><creatorcontrib>Tang, Yuanyuan</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Hao, Qian</creatorcontrib><creatorcontrib>Li, Xiaofei</creatorcontrib><creatorcontrib>Li, Xuemei</creatorcontrib><creatorcontrib>Mu, Rui</creatorcontrib><creatorcontrib>Niu, Min</creatorcontrib><creatorcontrib>Su, Xiaoming</creatorcontrib><creatorcontrib>Gao, Hengjun</creatorcontrib><title>Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia</title><title>Helicobacter (Cambridge, Mass.)</title><addtitle>Helicobacter</addtitle><description>Background
Geographic differences exist in the antibiotic resistance patterns of Helicobacter pylori. Personalized treatment regimens based on local or individual resistance data are essential. We evaluated the current status of H. pylori resistance in Ningxia, analyzed resistance‐related factors, and assessed the concordance of phenotypic and genotypic resistance.
Methods
Strains were isolated from the gastric mucosa of patients infected with H. pylori in Ningxia and relevant clinical information was collected. Phenotypic antibiotic susceptibility assays (Kirby–Bauer disk diffusion) and antibiotic resistance gene detection (Sanger sequencing) were performed.
Results
We isolated 1955 H. pylori strains. The resistance rates of H. pylori to amoxicillin, levofloxacin, clarithromycin, and metronidazole were 0.9%, 42.4%, 40.4%, and 94.2%, respectively. Only five tetracycline‐resistant and one furazolidone‐resistant strain were identified. Overall, 3.3% of the strains were sensitive to all six antibiotics. Multidrug‐resistant strains accounted for 22.9%, of which less than 20% were from Wuzhong. Strains isolated from women and patients with nonulcerative disease had higher rates of resistance to levofloxacin and clarithromycin. Higher rates of resistance to metronidazole, levofloxacin, and clarithromycin were observed in the older age group than in the younger age group. The kappa coefficients of phenotypic resistance and genotypic resistance for levofloxacin and clarithromycin were 0.830 and 0.809, respectively, whereas the remaining antibiotics showed poor agreement.
Conclusion
H. pylori antibiotic resistance is severe in Ningxia. Therefore, furazolidone, amoxicillin, and tetracycline are better choices for the empirical therapy of H. pylori infection in this region. Host sex, age, and the presence of ulcerative diseases may affect antibiotic resistance of the bacteria. Personalized therapy based on genetic testing for levofloxacin and clarithromycin resistance may be a future direction for the eradication therapy of H. pylori infection in Ningxia.</description><subject>Age</subject><subject>Age groups</subject><subject>Aged</subject><subject>Amoxicillin</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Clarithromycin</subject><subject>Clarithromycin - pharmacology</subject><subject>Clarithromycin - therapeutic use</subject><subject>Customization</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Resistance, Microbial</subject><subject>Empirical analysis</subject><subject>eradication therapy</subject><subject>Female</subject><subject>Furazolidone</subject><subject>Furazolidone - therapeutic use</subject><subject>gastric disease</subject><subject>Gastric mucosa</subject><subject>Gene sequencing</subject><subject>Genetic screening</subject><subject>genotype</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - microbiology</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Levofloxacin - pharmacology</subject><subject>Levofloxacin - therapeutic use</subject><subject>Metronidazole</subject><subject>Metronidazole - pharmacology</subject><subject>Metronidazole - therapeutic use</subject><subject>Microbial Sensitivity Tests</subject><subject>Patients</subject><subject>phenotype</subject><subject>Resistance factors</subject><subject>Retrospective Studies</subject><subject>Strains (organisms)</subject><subject>Tetracycline - pharmacology</subject><subject>Tetracycline - therapeutic use</subject><subject>Therapy</subject><issn>1083-4389</issn><issn>1523-5378</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp9kctKxDAUhoMo3he-gATc6KKaW9vUnQzqCINudF3SNHWOdJqapGofyPc046gLQQMhycl3PhJ-hA4oOaVxnM1Ne0pZkZE1tE1TxpOU53I97onkieCy2EI73j8RQlIuik20xXMiGBHpNnqfzJVTOhgHPoD22Da4n5vOhrEHjVUXoAIbb7AzPiKq02bJTE0L2lafnbgfW-sgwjWG4LG2zplWBbAdfoUwx4__-87xRTwFZ31vdIAXg30Y6hFDh2-he3wDtYc2GtV6s_-17qKHq8v7yTSZ3V3fTC5mieZSkiQTVHIqKU2VZsuSIDLPCG2EqjImZdVwxmgeC1xzrpmkdVUrJUWcWpCC76Ljlbd39nkwPpQL8Nq0reqMHXzJJCFUFIRlET36hT7ZwXXxdUuq4DTPszxSJytKx995Z5qyd7BQbiwpKZfZlTG78jO7yB5-GYdqYeof8jusCJytgFdozfi3qZxezlbKD0bYpdI</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Hu, Shengjuan</creator><creator>Zhou, Yan</creator><creator>Deng, Yanhong</creator><creator>Bo, Yang</creator><creator>Chen, Xianmei</creator><creator>Yang, Wei</creator><creator>Shi, Ruichun</creator><creator>Zhao, Wei</creator><creator>Hou, Zhanbing</creator><creator>Hu, Jianping</creator><creator>Liu, Jianguo</creator><creator>Zhang, Xilong</creator><creator>Yong, Heli</creator><creator>Wang, Ping</creator><creator>Li, Fei</creator><creator>Qi, Hailong</creator><creator>Wang, Xiaoyun</creator><creator>Jin, Lijuan</creator><creator>Cui, Ting</creator><creator>Yong, Haijiang</creator><creator>Li, Xue</creator><creator>Yang, Bin</creator><creator>Yu, Yuehua</creator><creator>Ma, Bin</creator><creator>Fu, Lei</creator><creator>Wang, Xuemei</creator><creator>Ma, Zhen</creator><creator>Tang, Na</creator><creator>You, Yanjie</creator><creator>Guo, Jianyang</creator><creator>Yu, Xiaobing</creator><creator>Yao, Li</creator><creator>Gao, Ruiping</creator><creator>Li, Yanling</creator><creator>Xin, Ruijuan</creator><creator>Liu, Jianfang</creator><creator>Cao, Zhenzi</creator><creator>Li, Hongliang</creator><creator>Ma, Linke</creator><creator>Ma, Shoucheng</creator><creator>Cao, Ying</creator><creator>Tang, Yuanyuan</creator><creator>Liu, Jun</creator><creator>Hao, Qian</creator><creator>Li, Xiaofei</creator><creator>Li, Xuemei</creator><creator>Mu, Rui</creator><creator>Niu, Min</creator><creator>Su, Xiaoming</creator><creator>Gao, Hengjun</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6676-8800</orcidid></search><sort><creationdate>202306</creationdate><title>Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia</title><author>Hu, Shengjuan ; Zhou, Yan ; Deng, Yanhong ; Bo, Yang ; Chen, Xianmei ; Yang, Wei ; Shi, Ruichun ; Zhao, Wei ; Hou, Zhanbing ; Hu, Jianping ; Liu, Jianguo ; Zhang, Xilong ; Yong, Heli ; Wang, Ping ; Li, Fei ; Qi, Hailong ; Wang, Xiaoyun ; Jin, Lijuan ; Cui, Ting ; Yong, Haijiang ; Li, Xue ; Yang, Bin ; Yu, Yuehua ; Ma, Bin ; Fu, Lei ; Wang, Xuemei ; Ma, Zhen ; Tang, Na ; You, Yanjie ; Guo, Jianyang ; Yu, Xiaobing ; Yao, Li ; Gao, Ruiping ; Li, Yanling ; Xin, Ruijuan ; Liu, Jianfang ; Cao, Zhenzi ; Li, Hongliang ; Ma, Linke ; Ma, Shoucheng ; Cao, Ying ; Tang, Yuanyuan ; Liu, Jun ; Hao, Qian ; Li, Xiaofei ; Li, Xuemei ; Mu, Rui ; Niu, Min ; Su, Xiaoming ; Gao, Hengjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-6418318115ac2c3884087601f4ab6288bf3221701f3c33c281dbdaa84aa8c4093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Age groups</topic><topic>Aged</topic><topic>Amoxicillin</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Clarithromycin</topic><topic>Clarithromycin - pharmacology</topic><topic>Clarithromycin - therapeutic use</topic><topic>Customization</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Resistance, Microbial</topic><topic>Empirical analysis</topic><topic>eradication therapy</topic><topic>Female</topic><topic>Furazolidone</topic><topic>Furazolidone - therapeutic use</topic><topic>gastric disease</topic><topic>Gastric mucosa</topic><topic>Gene sequencing</topic><topic>Genetic screening</topic><topic>genotype</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - microbiology</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Levofloxacin - pharmacology</topic><topic>Levofloxacin - therapeutic use</topic><topic>Metronidazole</topic><topic>Metronidazole - pharmacology</topic><topic>Metronidazole - therapeutic use</topic><topic>Microbial Sensitivity Tests</topic><topic>Patients</topic><topic>phenotype</topic><topic>Resistance factors</topic><topic>Retrospective Studies</topic><topic>Strains (organisms)</topic><topic>Tetracycline - pharmacology</topic><topic>Tetracycline - therapeutic use</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Shengjuan</creatorcontrib><creatorcontrib>Zhou, Yan</creatorcontrib><creatorcontrib>Deng, Yanhong</creatorcontrib><creatorcontrib>Bo, Yang</creatorcontrib><creatorcontrib>Chen, Xianmei</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Shi, Ruichun</creatorcontrib><creatorcontrib>Zhao, Wei</creatorcontrib><creatorcontrib>Hou, Zhanbing</creatorcontrib><creatorcontrib>Hu, Jianping</creatorcontrib><creatorcontrib>Liu, Jianguo</creatorcontrib><creatorcontrib>Zhang, Xilong</creatorcontrib><creatorcontrib>Yong, Heli</creatorcontrib><creatorcontrib>Wang, Ping</creatorcontrib><creatorcontrib>Li, Fei</creatorcontrib><creatorcontrib>Qi, Hailong</creatorcontrib><creatorcontrib>Wang, Xiaoyun</creatorcontrib><creatorcontrib>Jin, Lijuan</creatorcontrib><creatorcontrib>Cui, Ting</creatorcontrib><creatorcontrib>Yong, Haijiang</creatorcontrib><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Yang, Bin</creatorcontrib><creatorcontrib>Yu, Yuehua</creatorcontrib><creatorcontrib>Ma, Bin</creatorcontrib><creatorcontrib>Fu, Lei</creatorcontrib><creatorcontrib>Wang, Xuemei</creatorcontrib><creatorcontrib>Ma, Zhen</creatorcontrib><creatorcontrib>Tang, Na</creatorcontrib><creatorcontrib>You, Yanjie</creatorcontrib><creatorcontrib>Guo, Jianyang</creatorcontrib><creatorcontrib>Yu, Xiaobing</creatorcontrib><creatorcontrib>Yao, Li</creatorcontrib><creatorcontrib>Gao, Ruiping</creatorcontrib><creatorcontrib>Li, Yanling</creatorcontrib><creatorcontrib>Xin, Ruijuan</creatorcontrib><creatorcontrib>Liu, Jianfang</creatorcontrib><creatorcontrib>Cao, Zhenzi</creatorcontrib><creatorcontrib>Li, Hongliang</creatorcontrib><creatorcontrib>Ma, Linke</creatorcontrib><creatorcontrib>Ma, Shoucheng</creatorcontrib><creatorcontrib>Cao, Ying</creatorcontrib><creatorcontrib>Tang, Yuanyuan</creatorcontrib><creatorcontrib>Liu, Jun</creatorcontrib><creatorcontrib>Hao, Qian</creatorcontrib><creatorcontrib>Li, Xiaofei</creatorcontrib><creatorcontrib>Li, Xuemei</creatorcontrib><creatorcontrib>Mu, Rui</creatorcontrib><creatorcontrib>Niu, Min</creatorcontrib><creatorcontrib>Su, Xiaoming</creatorcontrib><creatorcontrib>Gao, Hengjun</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Helicobacter (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Shengjuan</au><au>Zhou, Yan</au><au>Deng, Yanhong</au><au>Bo, Yang</au><au>Chen, Xianmei</au><au>Yang, Wei</au><au>Shi, Ruichun</au><au>Zhao, Wei</au><au>Hou, Zhanbing</au><au>Hu, Jianping</au><au>Liu, Jianguo</au><au>Zhang, Xilong</au><au>Yong, Heli</au><au>Wang, Ping</au><au>Li, Fei</au><au>Qi, Hailong</au><au>Wang, Xiaoyun</au><au>Jin, Lijuan</au><au>Cui, Ting</au><au>Yong, Haijiang</au><au>Li, Xue</au><au>Yang, Bin</au><au>Yu, Yuehua</au><au>Ma, Bin</au><au>Fu, Lei</au><au>Wang, Xuemei</au><au>Ma, Zhen</au><au>Tang, Na</au><au>You, Yanjie</au><au>Guo, Jianyang</au><au>Yu, Xiaobing</au><au>Yao, Li</au><au>Gao, Ruiping</au><au>Li, Yanling</au><au>Xin, Ruijuan</au><au>Liu, Jianfang</au><au>Cao, Zhenzi</au><au>Li, Hongliang</au><au>Ma, Linke</au><au>Ma, Shoucheng</au><au>Cao, Ying</au><au>Tang, Yuanyuan</au><au>Liu, Jun</au><au>Hao, Qian</au><au>Li, Xiaofei</au><au>Li, Xuemei</au><au>Mu, Rui</au><au>Niu, Min</au><au>Su, Xiaoming</au><au>Gao, Hengjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia</atitle><jtitle>Helicobacter (Cambridge, Mass.)</jtitle><addtitle>Helicobacter</addtitle><date>2023-06</date><risdate>2023</risdate><volume>28</volume><issue>3</issue><spage>e12960</spage><epage>n/a</epage><pages>e12960-n/a</pages><issn>1083-4389</issn><eissn>1523-5378</eissn><abstract>Background
Geographic differences exist in the antibiotic resistance patterns of Helicobacter pylori. Personalized treatment regimens based on local or individual resistance data are essential. We evaluated the current status of H. pylori resistance in Ningxia, analyzed resistance‐related factors, and assessed the concordance of phenotypic and genotypic resistance.
Methods
Strains were isolated from the gastric mucosa of patients infected with H. pylori in Ningxia and relevant clinical information was collected. Phenotypic antibiotic susceptibility assays (Kirby–Bauer disk diffusion) and antibiotic resistance gene detection (Sanger sequencing) were performed.
Results
We isolated 1955 H. pylori strains. The resistance rates of H. pylori to amoxicillin, levofloxacin, clarithromycin, and metronidazole were 0.9%, 42.4%, 40.4%, and 94.2%, respectively. Only five tetracycline‐resistant and one furazolidone‐resistant strain were identified. Overall, 3.3% of the strains were sensitive to all six antibiotics. Multidrug‐resistant strains accounted for 22.9%, of which less than 20% were from Wuzhong. Strains isolated from women and patients with nonulcerative disease had higher rates of resistance to levofloxacin and clarithromycin. Higher rates of resistance to metronidazole, levofloxacin, and clarithromycin were observed in the older age group than in the younger age group. The kappa coefficients of phenotypic resistance and genotypic resistance for levofloxacin and clarithromycin were 0.830 and 0.809, respectively, whereas the remaining antibiotics showed poor agreement.
Conclusion
H. pylori antibiotic resistance is severe in Ningxia. Therefore, furazolidone, amoxicillin, and tetracycline are better choices for the empirical therapy of H. pylori infection in this region. Host sex, age, and the presence of ulcerative diseases may affect antibiotic resistance of the bacteria. Personalized therapy based on genetic testing for levofloxacin and clarithromycin resistance may be a future direction for the eradication therapy of H. pylori infection in Ningxia.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37042045</pmid><doi>10.1111/hel.12960</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6676-8800</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-4389 |
| ispartof | Helicobacter (Cambridge, Mass.), 2023-06, Vol.28 (3), p.e12960-n/a |
| issn | 1083-4389 1523-5378 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2800149026 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Age Age groups Aged Amoxicillin Amoxicillin - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotic resistance Antibiotics Clarithromycin Clarithromycin - pharmacology Clarithromycin - therapeutic use Customization Drug resistance Drug Resistance, Bacterial Drug Resistance, Microbial Empirical analysis eradication therapy Female Furazolidone Furazolidone - therapeutic use gastric disease Gastric mucosa Gene sequencing Genetic screening genotype Helicobacter Infections - drug therapy Helicobacter Infections - microbiology Helicobacter pylori Humans Levofloxacin Levofloxacin - pharmacology Levofloxacin - therapeutic use Metronidazole Metronidazole - pharmacology Metronidazole - therapeutic use Microbial Sensitivity Tests Patients phenotype Resistance factors Retrospective Studies Strains (organisms) Tetracycline - pharmacology Tetracycline - therapeutic use Therapy |
| title | Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A04%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20of%20phenotypic%20antibiotic%20resistance%20of%20Helicobacter%20pylori%20and%20its%20correlation%20with%20genotypic%20antibiotic%20resistance:%20A%20retrospective%20study%20in%20Ningxia&rft.jtitle=Helicobacter%20(Cambridge,%20Mass.)&rft.au=Hu,%20Shengjuan&rft.date=2023-06&rft.volume=28&rft.issue=3&rft.spage=e12960&rft.epage=n/a&rft.pages=e12960-n/a&rft.issn=1083-4389&rft.eissn=1523-5378&rft_id=info:doi/10.1111/hel.12960&rft_dat=%3Cproquest_cross%3E2800149026%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2809317767&rft_id=info:pmid/37042045&rfr_iscdi=true |